Is there an Indian generic version of Amivantamab?

Amivantamab (Amivantamab) is a targeted antibody drug used to treat a specific subtype of non-small cell lung cancer (NSCLC), which is epidermal growth factor receptor (EGFR) mutations and gene rearrangements. It is a bispecific antibody that binds to two different molecular targets simultaneously, thereby preventing the growth and spread of tumor cells.

Evantuzumab is not yet available in China, so patients cannot purchase it domestically and need to purchase it through foreign channels. There are only European versions of original drugs available abroad, and the price is relatively high, around 20,000 yuan. Currently, there are no officially marketed generic drugs of evantumumab.

Evantumumab is mainly used to treat EGFR gene mutations or MET gene exon14 Patients with NSCLC missing (METex14), a rare but aggressive subtype of lung cancer. Evantumumab is a bispecific antibody that inhibits both EGFR and MET signaling pathways by simultaneously binding to these two molecules. This helps inhibit the growth and spread of tumor cells.

Clinical trials have shown that evantumumab has significant therapeutic effects on patients with EGFR gene mutations or METex14NSCLC, including partial or complete remission of the disease, prolonged survival and alleviation of symptoms. Common side effects of evantumumab include fatigue, rash, nausea, vomiting, headache, etc. Like other medications, it may cause serious adverse reactions that require close monitoring and management.